The pCR rates were 41.5% and 29.5% in the HR-positive/HER2-positive and triple-negative breast cancer (TNBC; HR-negative/HER2-negative subtype), respectively. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.